Cargando…

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics

The increasing use of multiple immunomodulatory (IMD) agents for cancer therapies (e.g. antibodies targeting immune checkpoints, bispecific antibodies, and chimeric antigen receptor [CAR]-T cells), is raising questions on their potential immunogenicity and effects on treatment. In this review, we ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davda, Jasmine, Declerck, Paul, Hu-Lieskovan, Siwen, Hickling, Timothy P., Jacobs, Ira A., Chou, Jeffrey, Salek-Ardakani, Shahram, Kraynov, Eugenia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466770/ https://www.ncbi.nlm.nih.gov/pubmed/30992085 http://dx.doi.org/10.1186/s40425-019-0586-0

Ejemplares similares

Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration
por: Hu-Lieskovan, Siwen, et al.
Publicado: (2021)

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
por: Zhou, Yanchen, et al.
Publicado: (2022)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

What does PD-L1 positive or negative mean?
por: Ribas, Antoni, et al.
Publicado: (2016)

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
por: Scirocchi, Fabio, et al.
Publicado: (2021)

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
por: Diab, Adi, et al.
Publicado: (2022)

The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling
por: Yin, Liusong, et al.
Publicado: (2015)

Immunogenicity and immunomodulatory effects of the human chondrocytes, hChonJ
por: Lim, Chae-Lyul, et al.
Publicado: (2017)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Assessing the Immunogenicity of Biopharmaceuticals
por: Pineda, Carlos, et al.
Publicado: (2016)

OX40:OX40L axis: emerging targets for improving poxvirus‐based CD8(+) T‐cell vaccines against respiratory viruses
por: Goulding, John, et al.
Publicado: (2011)

Exosomes as a predictor tool of acquired resistance to melanoma treatment
por: Goedert, Lucas, et al.
Publicado: (2014)

Antibody Therapeutics in Oncology
por: Wold, Erik D, et al.
Publicado: (2016)

Oncologic immunomodulatory agents in patients with cancer and COVID-19
por: Jee, Justin, et al.
Publicado: (2021)

Editorial: Follicular Helper T Cells in Immunity and Autoimmunity
por: Cicalese, Maria Pia, et al.
Publicado: (2020)

CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer
por: Marcovecchio, Paola Marie, et al.
Publicado: (2021)

Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications
por: Salek-Ardakani, Shahram, et al.
Publicado: (2023)

Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
por: Zhao, Yuan, et al.
Publicado: (2012)

EZH2 as a Regulator of CD8+ T Cell Fate and Function
por: Stairiker, Christopher J., et al.
Publicado: (2020)

The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects
por: Declerck, Paul, et al.
Publicado: (2017)

Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
por: Blanco, Belén, et al.
Publicado: (2021)

A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 2—Model Applications
por: Chen, X, et al.
Publicado: (2014)

A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 1—Theoretical Model
por: Chen, X, et al.
Publicado: (2014)

The immunogenicity of chimeric antibodies
Publicado: (1989)

Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology
por: Feld, Jonathan, et al.
Publicado: (2013)

The dark side of immunotherapy
por: Okwundu, Nwanneka, et al.
Publicado: (2021)

First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma
por: Wang, Xuechen, et al.
Publicado: (2021)

The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance
por: Opolka-Hoffmann, Eugenia, et al.
Publicado: (2021)

Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases
por: McMahan, Zsuzsanna H, et al.
Publicado: (2014)

Sialic acids as cellular markers of immunomodulatory action of dexamethasone on glioma cells of different immunogenicity
por: Wielgat, Przemyslaw, et al.
Publicado: (2018)

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells
por: Matsushita, Maiko, et al.
Publicado: (2023)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

Prediction of immunogenicity for humanized and full human therapeutic antibodies
por: Liang, Shide, et al.
Publicado: (2020)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
por: Moser, Justin C., et al.
Publicado: (2019)

Local Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors
por: Silva-Pilipich, Noelia, et al.
Publicado: (2023)

Inducing immunogenic cell death in immuno-oncological therapies
por: Ti, Dongdong, et al.
Publicado: (2022)

Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity
por: van Schie, Karin A, et al.
Publicado: (2015)

Assessing the Immunomodulatory Effect of Size on the Uptake and Immunogenicity of Influenza- and Hepatitis B Subunit Vaccines In Vitro
por: Heida, Rick, et al.
Publicado: (2022)

Immunomodulatory and pro-oncologic effects of ketamine and isoflurane anesthetics in a murine model
por: Abrahams, Dominique, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8rk316ofevk6kbs84k21ufgdvv